Siemens Healthcare Diagnostics is partnering with Janssen Pharmaceutica in an effort to develop and commercialize a companion diagnostic test for an early-stage compound being developed by Janssen. The compound targets autoantibodies directed against the human β1-adrenergic receptor (β1-AR), which may contribute to the development of heart failure.
Under the terms of the agreement, investigators at Siemens’ clinical lab will work collaboratively with Janssen scientists to design immunoassay-based companion diagnostic tests for use in the latter firm’s clinical studies. At the same time, Siemens will develop and validate an in vitro diagnostic test as a companion diagnostic for the Janssen therapeutic product, the firms said. The resulting test is slated to be “broadly commercialized on Siemens’ central laboratory automated immunoassay systems,” they added in a statement.
“Our relationship with Janssen marks an important next step in Siemens’ personalized medicine strategy,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. “As a leading clinical diagnostics company, with the tools and technologies to help define the future of patient care, we are looking forward to collaborating with Janssen and extending their position in cardiac therapies.”
